The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Guy Yehiav In the U.S., ...

Drugs are man-made miracles. They enhance our health, cure diseases, and extend our lives. However, drug development is not easy. It is a remarkably long, expensive, and complex process. On average, ...

Bari Kowal, Senior Vice President, Development Operations & Portfolio Management at Regeneron Clinical trial innovation is a hot topic, but it’s not a new one. The first fully virtual randomized trial ...

Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and expectations from regulators, payers, and patients continue to rise. Meanwhile, ...

AstraZeneca's $15 billion pledge to its China operations highlights the country's advantages. But other regions are also hoping to host more clinical studies.

The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

With the continuing cuts to US Food and Drug Administration (FDA) staffing, the pharmaceutical and biotechnology industries are communicating increasing concern about potential product development ...

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...